Company profile
MediciNova, Inc.
NASDAQ: MNOV · Healthcare · Biotechnology
PublicHQ La Jolla, CACIK 0001226616Reports USD
#946 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
41DFH 50DQ 40GM 10SS 52
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ growth stability, 3-yr revenue growth
Methodology →Revenue TTM
$920.5k
Rev growth YoY (TTM)
+583.9%
Net income (FY)
-$12.0M
Employees
6
as of 2026-08-19
Market cap
$66.0M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$409.7k$409.7k2025
Net income-$12.0M-$12.0M2025
Operating income-$13.3M-$13.3M2025
Total assets$45.6M$45.6M2025
Liabilities$4.0M$4.0M2025
Equity$41.6M$41.6M2025
Revenue trend
FY2012 – FY2025 · USD
FY12
FY12
FY12
FY13
FY13
FY21
FY23
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is MediciNova, Inc.’s revenue?
MediciNova, Inc. booked $409.7k in FY2025 revenue, contracting 59% year over year — slower than 84% of Healthcare companies we track, at a -2928.8% net margin.
Peers · Healthcare
Niki BioSolutions, Inc.32DAequus Pharmaceuticals Inc.——Amarantus BioScience Holdings, Inc.——Cartesian Therapeutics, Inc.40DiBio, Inc.49DNeurogenesis, Inc.——Key facts
CEOYuichi Iwaki
SectorHealthcare
IndustryBiotechnology
HeadquartersLa Jolla, CA
ExchangeNASDAQ: MNOV
Employees6
IPO date2006-12-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.